QuoTrend
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNews
DashboardScreenCompareStrategiesPortfolioSectorsHeatmapsInsiderFuturesForexCryptoCalendarNewsMore
⌘K
Help
QuoTrend
PAGEHome
HomePricingContactHelpTermsPrivacy
Quotes delayed 15 minutes for NASDAQ, NYSE and AMEX.
© 2026 QuoTrend
Screen

PRME

QT56Prime Medicine, Inc.
NASDAQ·Healthcare·Biotechnology·USA
Latest market price
3.23
+0.07+2.22%
OverviewShort InterestFilings
PRMEQT56Prime Medicine, Inc.·NASDAQ
OverviewShort InterestFilings
3.23+2.22%
TA
Loading chart...
Screen all →
VRTX-1.60%$451.63REGN+0.33%$609.94ARGX-1.63%$877.72ALNY-1.64%$278.09RVMD+3.31%$162.99MRNA+3.50%$63.96UTHR-2.70%$536.59BNTX-1.44%$90.89
Snapshot
Index-P/E-EPS (ttm)
-1.27
Insider Own39.71%
Shs Outstand180.62M
Perf Week14.54%
Market Cap570.75MForward P/E-EPS next Y-0.91Insider Trans0.00%Shs Float-Perf Month19.63%
Enterprise Value621.16MPEG-EPS next Q-0.24Inst Own-Short Float-Perf Quarter-12.23%
Income-202331280.00P/S141.49EPS this Y21.34%Inst Trans-Short Ratio-Perf Half Y-16.75%
Sales4.03MP/B7.30EPS next Y9.19%ROA-67.31%Short Interest-Perf YTD-6.92%
Book/sh0.43P/C-EPS next 5Y-ROE-188.82%52W High6.94 -53.46%Perf Year99.38%
Cash/sh0.75P/FCF-EPS past 3/5Y-ROIC-77.39%52W Low1.55 108.39%Perf 3Y-
Dividend Est.-EV/EBITDA-3.25Sales past 3/5Y- 0.00%Gross Margin-1082.70%Volatility5.59% 5.77%Perf 5Y-
Dividend TTM-EV/Sales153.98EPS Y/Y TTM25.53%Oper. Margin-5121.77%ATR (14)0.27Perf 10Y-
Dividend Ex-DateMar 22, 2018Quick Ratio3.80Sales Y/Y TTM33.33%Profit Margin-4917.55%RSI (14)53.51Recom2.44
Dividend Gr. 3/5Y-Current Ratio3.80EPS Q/Q30.00%SMA204.65%Beta2.40Target Price17.25
Payout0.00%Debt/Eq1.49Sales Q/Q0.00%SMA50-2.22%Rel Volume1.42Prev Close3.16
Employees214LT Debt/Eq0.89EarningsAug 06SMA200-18.23%Avg Volume2.46MPrice3.23
IPO DateOct 20, 2022Option/ShortYes / YesEPS/Sales Surpr.-16.67% -50.00%Net Debt/EBITDA-0.26Volume3,498,693Change2.22%
Analyst Ratings
DateActionAnalystRatingTarget
May-27-25DowngradeCitigroupBuy → Neutral
May-20-25DowngradeJP MorganOverweight → Neutral
May-20-25DowngradeHC Wainwright & Co.Buy → Neutral
May-16-24UpgradeCitigroupNeutral → Buy
May-07-24ReiteratedJefferies$15
Apr-02-24InitiatedWedbushBuy$12
Oct-09-23ReiteratedBMO Capital$19
Nov-14-22InitiatedMorgan Stanley$23
Latest News
Jun-18-26
Jun-18-2608:08AM
Prime Medicine Receives New Zealand's Regulator Clearance For Its Clinical Trial Application For PM577a To Treat Wilson DiseaseBenzinga
Jun-13-26
Jun-13-2604:51AM
Prime Medicine's Prime Editing Is Worth The RiskSeekingAlpha
Company
Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
Total Revenue453
Upgrade your experience to unlock full historical data
Cost of Goods Sold Incl. D&A4870
Gross Profit-44-33
Selling, General and Administrative Excl. Other565250
Research and Development154161155
Other Operating Expense-47-70
Operating Income-207-208-202
Interest Expense
000
Unusual Expense
———
Non-Operating Income (Expense)-9-7-7
Net Income Before Taxes-199-201-196
Income Taxes000
Consolidated Net Income-199-201-196
Net Income From Continuing Operations-199-201-196
Net Income-199-201-196
EPS (Recurring)-1.27-1.35-1.65
EPS (Basic, Before Extraordinaries)-1.27-1.35-1.65
EPS (Diluted)-1.27-1.35-1.65
EBITDA-191-196-190
Other After Tax Adjustments
———
Stock Option Compensation Expense
———
Price To Earnings Ratio
———
Price To Sales Ratio142.93103.41—
Gross Margin-1,100.00-60.00100.00
Operating Margin-5,175.00-4,160.00-6,733.33
Net Margin-4,975.00-4,020.00-6,533.33
Shares Outstanding177149119
Market Capitalization572517—
Operating Lease Expense
———
Insider Trading Volume
$3.62$3.38$3.13$2.88$2.64● Close Price0.00M8.74M17.47M26.21M34.95MUSD Trades VolumeJunJulAugSepOctNovDec2026FebMarAprMayJun
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
GV 2021 GP, L.L.C.10% OwnerAug 01 '25Buy3.301,500,0004,950,0003,262,440Aug 05 12:00 AM
ARCH Venture Partners X, LLC10% OwnerAug 01 '25Buy3.303,030,3009,999,9906,230,300Aug 01 12:00 AM
NELSEN ROBERTdirector, 10 percent owner:Aug 01 '25Buy3.303,030,3009,999,9906,230,300Aug 01 12:00 AM
ARCH Venture Partners XII, LLC10% OwnerAug 01 '25Buy3.303,030,3009,999,9906,230,300Aug 01 12:00 AM
Liu David R.10% OwnerJun 30 '25Buy2.5221,00052,83020,240,945Jul 01 12:00 AM
Liu David R.10% OwnerJun 23 '25Buy2.1621,00045,40220,219,945Jun 23 12:00 AM
Liu David R.10% OwnerJun 16 '25Buy1.4921,00031,19620,198,945Jun 16 12:00 AM
Liu David R.10% OwnerJun 11 '25Buy1.6021,00033,59020,177,945Jun 12 12:00 AM
LEE ANN L.Chief Technical OfficerMay 21 '25Buy1.13100,000113,000100,000May 22 12:00 AM
Reine AllanChief Executive OfficerMay 21 '25Buy1.18125,000147,150125,000May 22 12:00 AM
Brudnick RichardChief Business OfficerMay 20 '25Buy1.1920,00023,79020,000May 22 12:00 AM
NELSEN ROBERTdirector, 10 percent owner:Feb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 12:00 AM
ARCH Venture Partners XII, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 12:00 AM
ARCH Venture Partners X, LLC10% OwnerFeb 15 '24Buy6.253,200,00020,000,0003,200,000Feb 20 12:00 AM
GV 2019 GP, L.L.C.10% OwnerJun 21 '23Sale14.9719,003284,4960Jun 22 12:00 AM
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR